Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma

Cost-Effectiveness Study of Pegylated Recombinant Human Granulocyte Colony-stimulating Factor(PEG-rhG-CSF) in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma

This is a pharmacoeconomic research to explore the cost-effectiveness of PEG-rhG-CSF and rhG-CSF in prophylactic treatment of neutropenia in lymphoma patients. It should provide more scientific basis for clinical decision-making.

Inclusion Criteria:

• 18-65 years
• histologically confirmed de novo Non Hodgkin's lymphoma (except highly aggressive lymphoma such as lymphoblastic lymphoma and Burkitt lymphoma)
• plan to be given 6-8 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) ± Rituximab (R)
• KPS ≥70
• plan continuous PEG-rhG-CSF or rhG-CSF adiministration after at least 3 cycles of treatment for neutropenia prophylactic treatment
• absolute neutrophil count≥1.5×109/L，platelet count ≥100× 109/L，hemoglobin≥90g/L，while blood cell count≥3.0×109/L，without bleeding signs
• adquate liver and renal function as protocol discribed
• no serious cardiovascular disease as protocol discribed
• under good mental conditions and informed consented
• potential benefit for subjects based on investigators' decision

Exclusion Criteria:

• history of hematopoetic stem cell transplantationor organ transplantation
• uncontrollable infection
• allergic to study drugs or ingredients
• accepted any other investigational drug or participated another interventional study within 30 days during screening period
• other uncontrollable conditions judged by the investigator
• breast-feeding , pregnant or plan to be pregnant during study observation period